US · GNLX · BIOTECHNOLOGY
Genelux Corporation (GNLX) intrinsic value and stock valuation
$2.17as of 2026-11-21 · Mkt cap 119.28M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Genelux Corporation DCF and intrinsic value
InvestorsCraft values GNLX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from GNLX’s statements →
Genelux Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10K | $10K | $170K | $11.1M | $0.00 |
| Operating income | -$-33.21M | -$-31.7M | -$-24.16M | -$-3.01M | -$-14.61M |
| Net income | -$-32.15M | -$-29.87M | -$-28.3M | -$-5.21M | -$-17.8M |
| EPSd | -$-864.71K | -$-949.76K | -$-1.16M | -$-212.22K | -$-753.6K |
| Operating cash flow | -$-25.27M | -$-21.23M | -$-20.27M | -$-3.57M | -$-6.58M |
| Capital expenditure | -$-1.1M | -$-380K | -$-1.02M | -$-50K | $0.00 |
| Free cash flow | -$-26.37M | -$-21.61M | -$-21.3M | -$-3.62M | -$-6.58M |
| Total assets | $19M | $34.7M | $27.9M | $5.53M | $8.13M |
| Total debt | $1.69M | $1.87M | $2.52M | $26.4M | $25.3M |
| Net debt | -$-3.65M | -$-6.7M | -$-6.9M | $26M | $20.8M |
| Total equity | $11.5M | $26.3M | $19.5M | -$-35.78M | -$-33.11M |
| Cash and short-term investments | $14.6M | $30.9M | $23.2M | $400K | $4.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10K | $10K | $170K | $11.1M | $0.00 |
| Cost of revenue | $570K | $900K | $1.02M | $970K | $900K |
| Gross profit | -$-570K | -$-900K | -$-850K | $10.1M | -$-900K |
| Research and development expenses | $19.9M | $19M | $12.8M | $9.08M | $6.32M |
| Selling, general and administrative expenses | $13.4M | $12.7M | $11.6M | $5M | $8.29M |
| Other expenses | -$-570K | -$-900K | -$-1.02M | -$-970K | -$-900K |
| Operating expenses | $32.7M | $30.8M | $23.3M | $13.1M | $13.7M |
| Cost and expenses | $33.2M | $31.7M | $24.3M | $14.1M | $14.6M |
| Interest income | $1.07M | $1.46M | $240K | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $3.97M | $1.41M | $1.81M |
| Depreciation and amortization | $570K | $900K | $1.02M | $970K | $900K |
| Ebitda | -$-31.57M | -$-28.97M | -$-26.46M | -$-1.73M | -$-13.67M |
| Operating income | -$-33.21M | -$-31.7M | -$-24.16M | -$-3.01M | -$-14.61M |
| Total other income/expenses, net | $1.07M | $1.83M | -$-4.13M | -$-1.09M | -$-1.76M |
| Income before tax | -$-32.15M | -$-29.87M | -$-28.3M | -$-4.11M | -$-16.38M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $1.1M | $0.00 |
| Net income | -$-32.15M | -$-29.87M | -$-28.3M | -$-5.21M | -$-17.8M |
| Weighted average shares outstanding | $37.2M | $31.5M | $24.4M | $24.6M | $23.6M |
| Weighted average diluted shares outstanding | $37.2M | $31.5M | $24.4M | $24.6M | $23.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $14.6M | $30.9M | $23.2M | $400K | $4.5M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $15.1M | $31.6M | $24.2M | $1.89M | $5.82M |
| Property, plant and equipment, net | $3.75M | $3.08M | $3.6M | $1.98M | $2.21M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $3.9M | $3.17M | $3.69M | $3.64M | $2.3M |
| Total assets | $19M | $34.7M | $27.9M | $5.53M | $8.13M |
| Accounts payable | $4.36M | $5.57M | $3.78M | $6.78M | $4.46M |
| Short-term debt | $430K | $330K | $1.31M | $16.7M | $6.56M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $170K | $4.5M |
| Total current liabilities | $6.22M | $6.9M | $6.55M | $31.6M | $22.5M |
| Long-term debt | $1.26M | $1.54M | $1.87M | $9.69M | $18.8M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $1.26M | $1.54M | $1.87M | $9.69M | $18.8M |
| Capital lease obligations | $1.69M | $1.54M | $2.52M | $1.43M | $1.13M |
| Total liabilities | $7.48M | $8.44M | $8.42M | $41.3M | $41.2M |
| Common stock | $40K | $40K | $30K | $10K | $10K |
| Retained earnings | -$-283.54M | -$-251.39M | -$-221.52M | -$-189.78M | -$-184.58M |
| Accumulated other comprehensive income (loss) | $10K | $60K | $10K | $0.00 | $0.00 |
| Total equity | $11.5M | $26.3M | $19.5M | -$-35.78M | -$-33.11M |
| Total investments | $9.26M | $22.3M | $13.8M | $0.00 | $0.00 |
| Total debt | $1.69M | $1.87M | $2.52M | $26.4M | $25.3M |
| Net debt | -$-3.65M | -$-6.7M | -$-6.9M | $26M | $20.8M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-32.15M | -$-29.87M | -$-28.3M | -$-5.21M | -$-16.38M |
| Depreciation and amortization | $240K | $900K | $1.02M | $970K | $900K |
| Stock-based compensation | $5.87M | $6.07M | $5.2M | $2.42M | $4.27M |
| Change in working capital | -$-1.05M | $750K | -$-3.28M | -$-1.69M | $4.08M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-1.21M | $2.16M | -$-2.36M | $2.31M | $750K |
| Net cash provided by operating activities | -$-25.27M | -$-21.23M | -$-20.27M | -$-3.57M | -$-6.58M |
| Investments in property, plant and equipment | -$-1.1M | -$-380K | -$-1.02M | -$-50K | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $12.1M | -$-8.13M | -$-14.72M | -$-50K | $0.00 |
| Common stock issued | $9.89M | $27.8M | $39.7M | $120K | $140K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $9.89M | $28.5M | $44M | -$-480K | -$-270K |
| Net change in cash | -$-3.23M | -$-850K | $9.02M | -$-4.1M | -$-6.86M |
| Cash at end of period | $5.33M | $8.56M | $9.42M | $400K | $4.5M |
| Operating cash flow | -$-25.27M | -$-21.23M | -$-20.27M | -$-3.57M | -$-6.58M |
| Capital expenditure | -$-1.1M | -$-380K | -$-1.02M | -$-50K | $0.00 |
| Free cash flow | -$-26.37M | -$-21.61M | -$-21.3M | -$-3.62M | -$-6.58M |
Line items
Line items
Line items
About Genelux Corporation
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
- CEO
- Thomas D. Zindrick
- Employees
- 26
- Beta
- 0.57
Explore
Frequently asked questions
What is the intrinsic value of Genelux Corporation (GNLX)?
Genelux Corporation (GNLX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is GNLX undervalued?
GNLX trades at a price of $2.17 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.